Becton, Dickinson and Company (BD) is a leading global medical technology company that operates through three primary business segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment is the largest revenue contributor (representing over 50% of total revenue), focusing on medication delivery and management solutions, including peripheral IV catheters, prefillable syringes, and automated dispensing cabinets like the Pyxis system. The BD Life Sciences segment provides products for specimen collection, flow cytometry, and advanced diagnostic systems used in clinical oncology, immunology, and infectious disease testing. The BD Interventional segment offers surgical, endovascular, urological, and critical care products, a portfolio significantly bolstered by the strategic acquisitions of CareFusion and C.R. Bard. Geographically, BD maintains a massive global footprint, generating roughly half of its revenue from the United States and the remainder from international markets. The company's competitive position is anchored by its scale, its extensive portfolio of essential medical devices, strong recurring revenue from consumables, and continuous innovation in healthcare automation and digital health solutions.
